The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
Animals
Antineoplastic Agents
/ pharmacology
Cisplatin
/ pharmacology
Down-Regulation
Drug Resistance, Neoplasm
Female
Humans
Mice
MicroRNAs
/ metabolism
Molecular Targeted Therapy
Mutation
Neoplasm Grading
Neoplastic Stem Cells
/ metabolism
Ovarian Neoplasms
/ drug therapy
Proto-Oncogene Proteins
/ genetics
Tumor Cells, Cultured
Wnt Signaling Pathway
/ genetics
beta Catenin
/ antagonists & inhibitors
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
15
06
2020
revised:
11
12
2020
accepted:
09
02
2021
pubmed:
13
2
2021
medline:
14
9
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Wnt signaling is a major driver of stemness and chemoresistance in ovarian cancer, yet the genetic drivers that stimulate its expression remain largely unknown. Unlike other cancers, mutations in the Wnt pathway are not reported in high-grade serous ovarian cancer (HGSOC). Hence, a key challenge that must be addressed to develop effective targeted therapies is to identify nonmutational drivers of Wnt activation. Using an miRNA sensor-based approach, we have identified miR-181a as a novel driver of Wnt/β-catenin signaling. miR-181a
Identifiants
pubmed: 33574092
pii: 0008-5472.CAN-20-2041
doi: 10.1158/0008-5472.CAN-20-2041
pmc: PMC8137569
mid: NIHMS1675098
doi:
Substances chimiques
Antineoplastic Agents
0
CTNNB1 protein, human
0
MIrn181 microRNA, human
0
MicroRNAs
0
Proto-Oncogene Proteins
0
SFRP4 protein, human
0
beta Catenin
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2044-2055Subventions
Organisme : NCI NIH HHS
ID : P30 CA043703
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197780
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008803
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
BMC Cancer. 2018 Aug 3;18(1):783
pubmed: 30075764
Ann Oncol. 2016 Aug;27(8):1511-9
pubmed: 27194815
Cancer Lett. 2011 Aug 1;307(1):62-71
pubmed: 21481528
Nat Commun. 2014;5:2977
pubmed: 24394555
Clin Cancer Res. 2013 Apr 15;19(8):1972-80
pubmed: 23444212
Nat Cell Biol. 2010 May;12(5):468-76
pubmed: 20418870
Stem Cell Reports. 2019 Jan 8;12(1):122-134
pubmed: 30629937
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Front Oncol. 2020 Jul 17;10:1039
pubmed: 32766133
PLoS One. 2013;8(1):e54362
pubmed: 23326605
Cancer Cell. 2013 Dec 9;24(6):751-65
pubmed: 24332043
Nat Methods. 2012 Jul 01;9(8):840-6
pubmed: 22751203
Sci Rep. 2019 Jan 22;9(1):307
pubmed: 30670712
PLoS One. 2012;7(2):e31885
pubmed: 22363760
Gynecol Oncol. 2013 Dec;131(3):772-9
pubmed: 24125749
Elife. 2017 Oct 31;6:
pubmed: 29087294
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nat Rev Genet. 2009 Aug;10(8):578-85
pubmed: 19609263
Oncol Rep. 2017 Mar;37(3):1469-1476
pubmed: 28184923
Oncotarget. 2015 Sep 15;6(27):23720-34
pubmed: 26125441
Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52
pubmed: 21502498
Cancer Res. 2015 Apr 1;75(7):1482-94
pubmed: 25670168
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):229-37
pubmed: 26849897
Gynecol Oncol. 2004 Oct;95(1):9-15
pubmed: 15385104
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Nat Commun. 2020 Jun 26;11(1):3231
pubmed: 32591511
Nat Commun. 2015 Jun 17;6:7419
pubmed: 26080861
Biomark Med. 2015;9(3):241-57
pubmed: 25731210
Oncogene. 2015 Apr 30;34(18):2297-308
pubmed: 24954508